1 completed, 1 terminated, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow TAK228: new trials by email Literature Review of TAK228 trials Research Report on TAK228
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas Brentuximab Vedotin, TAK228, Glucose Monitor - Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Classical Hodgkin Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2018-03-01 | 2018-01-17 | |
| Phase II Study of TAK228 in Relapsed Lymphoma TAK228, Blood Sugar Testing - Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-03-01 | 2020-03-12 |
Fallopian Tube Neoplasms (1) · Lymphoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Ovarian Neoplasms (1)
M.D. Anderson Cancer Center (2) · Imperial College London (1)
Germany (1) · United Kingdom (1) · United States (1)
Jason R. Westin, MD (1) · Jonathan Krell (1) · Michelle A. Fanale, MD (1)